WO2017017604A1 - Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof - Google Patents

Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof Download PDF

Info

Publication number
WO2017017604A1
WO2017017604A1 PCT/IB2016/054446 IB2016054446W WO2017017604A1 WO 2017017604 A1 WO2017017604 A1 WO 2017017604A1 IB 2016054446 W IB2016054446 W IB 2016054446W WO 2017017604 A1 WO2017017604 A1 WO 2017017604A1
Authority
WO
WIPO (PCT)
Prior art keywords
substantially pure
sodium salt
pure amorphous
simeprevir
simeprevir sodium
Prior art date
Application number
PCT/IB2016/054446
Other languages
French (fr)
Other versions
WO2017017604A9 (en
Inventor
Mahesh Ramkumar Kolekar
Dinesh Jayantibhai Paghdar
Yuvraj Atmaram Chavan
Purna Chandra Ray
Girij Pal Singh
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2017017604A1 publication Critical patent/WO2017017604A1/en
Publication of WO2017017604A9 publication Critical patent/WO2017017604A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to substantially pure amorphous forms of Simeprevir sodium and the process for preparation thereof.
  • HCV Hepatitis C virus
  • protease inhibitors particularly those selectively targeting HCV serine protease, has great potential to be useful in treating HCV infections in patients by inhibiting HCV replication.
  • Simeprevir (TMC-435) is a new protease inhibitor jointly developed by Janssen and Medivir, therapeutic gene-1 chronic hepatitis C patients with compensated liver diseases. Simeprevir is considered so by blocking HCV protease survive and replicate within host cells to produce effects.
  • Simeprevir sodium (trade name Olysio) was approved by the USFDA, for treatment in combination therapy with pegylated interferon and ribavirin for chronic hepatitis C genotype -1 virus (HCV) infection.
  • Simeprevir is represented by the following formula
  • US20110306634 describes an amorphous form of Simeprevir sodium salt. This application also described the preparation of amorphous Simeprevir sodium salt by spray- drying.
  • Polymorphism is a property of some compounds. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties.
  • Polymorphs are different solids having the same molecular structure, yet having distinct physical properties when compared to other polymorphs of the same molecular structure.
  • the discovery of new polymorphs and solvates of a pharmaceutical active compound provides an opportunity to improve the performance of a drug product in terms of its bioavailability or release profile in vivo, or it may have improved stability or advantageous handling properties.
  • Polymorphism is an unpredictable property of any given compound. This subject has been reviewed in recent articles, including A. Goho, "Tricky Business," Science News, August 21, 2004. In general, one cannot predict whether there will be more than one form for a compound, how many forms will eventually be discovered, or how to prepare any previously unidentified form.
  • Figure 1 illustrates X-ray powder diffraction pattern of substantially pure amorphous Simeprevir sodium designated as LI.
  • FIG. 1 illustrates Differential Scanning Calorimetry (DSC) of LI.
  • Figure 3 illustrates X-ray powder diffraction pattern of substantially pure amorphous Simeprevir sodium designated as L2.
  • FIG. 4 illustrates Differential Scanning Calorimetry (DSC) of L2. Summary of the invention:
  • the present invention provides substantially pure amorphous forms of Simeprevir sodium designated as LI. In accordance with another embodiment, the present invention provides substantially pure amorphous forms of Simeprevir sodium designated as L2.
  • the present invention provides the process for preparation of substantially pure amorphous forms of simeprevir sodium salt.
  • the present invention provides for pharmaceutical compositions comprising said substantially amorphous forms of Simeprevir sodium. Detailed description:
  • substantially pure amorphous as used herein is intended to mean that amorphous Simeprevir sodium with certain degree of crystallinity.
  • the present invention provides Simeprevir sodium in a substantially pure amorphous form designated as LI, characterized by X-ray powder diffraction pattern as depicted in Fig. 1.
  • the PXRD pattern of substantially pure amorphous Simeprevir sodium comprises of crystalline peaks at 8.05° ⁇ 0. 2° 2 ⁇ and 17.96° ⁇ 0.2° 2 ⁇ .
  • the present invention provides Simeprevir sodium salt in a substantially pure amorphous form designated as L2, characterized by X-ray powder diffraction pattern as depicted in Fig. 3.
  • the PXRD pattern of substantially pure amorphous Simeprevir sodium comprises of crystalline peaks at 8.78° ⁇ 0. 2° 2 ⁇ , 11.36 ° ⁇ 0.2° 2 ⁇ and 29.69° ⁇ 0.2° 2 ⁇ .
  • step (ii) adding anti-solvent to the mixture of step (i);
  • the organic solvent used in step (i) is selected from but not limited to methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, amyl alcohol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, dioxane and/or mixtures thereof.
  • the reaction of step (i) is carried out at a temperature of 0°C to reflux temperature of the solvent.
  • the anti-solvent used in step (ii) is selected from but not limited to n-pentane, n-hexane, n- heptane, cyclohexane, toluene, xylene, and/or water and mixtures thereof.
  • the isolation of the substantially pure amorphous Simeprevir sodium salt is carried out by conventional techniques known in the prior art such as filtration, concentration, evaporation etc.; and drying the product include all techniques known to those skilled in the art, such as heating, applying vacuum, circulating air or gas, adding a desiccant, evaporation, or the like, or any combination thereof.
  • the present invention provides a pharmaceutical composition comprising substantially pure amorphous form LI and form L2 of Simeprevir sodium with pharmaceutically acceptable excipients.
  • substantially pure amorphous form LI and form L2 of Simeprevir sodium can be formulated into various pharmaceutical compositions like powder, granules, capsules, tablets, pellets etc.
  • compositions may be utilized as required for conversion of the substantially amorphous form of Simeprevir sodium salt into the final pharmaceutical dosage forms and include, for example, any one or more of diluents, binders, stabilizers, lubricants, glidants, disintegrating agents, surfactants, and other additives that are commonly used in solid pharmaceutical dosage form preparations.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to substantially pure amorphous forms (L1 and L2) of Simeprevir sodium salt, process for the preparation and pharmaceutical composition thereof.

Description

SUBSTANTIALLY PURE AMORPHOUS SIMEPREVIR SODIUM SALT AND
THE PROCESS FOR PREPARATION THEREOF Field of the invention The present invention relates to substantially pure amorphous forms of Simeprevir sodium and the process for preparation thereof.
Background of the invention Hepatitis C virus (HCV) is the major etiological agent of 90% of all cases of non-A, non- 13 hepatitis. The incidence of HCV infection is becoming an increasingly severe public health concern with 2-15% individuals infected worldwide. While primary infection with HCV is often asymptomatic, most HCV infections progress to a chronic state that can persist for decades. Of those with chronic HCV infections, it is believed that about 20- 50% will eventually develop chronic liver disease (e.g. cirrhosis) and 20-30% of these cases will lead to liver failure or liver cancer. As the current HCV-infected population ages, the morbidity and mortality associated with HCV are expected to triple.
The use of protease inhibitors, particularly those selectively targeting HCV serine protease, has great potential to be useful in treating HCV infections in patients by inhibiting HCV replication.
Simeprevir (TMC-435) is a new protease inhibitor jointly developed by Janssen and Medivir, therapeutic gene-1 chronic hepatitis C patients with compensated liver diseases. Simeprevir is considered so by blocking HCV protease survive and replicate within host cells to produce effects.
Simeprevir sodium (trade name Olysio) was approved by the USFDA, for treatment in combination therapy with pegylated interferon and ribavirin for chronic hepatitis C genotype -1 virus (HCV) infection. Simeprevir is represented by the following formula
(i);
Figure imgf000004_0001
(I)
US20110306634 describes an amorphous form of Simeprevir sodium salt. This application also described the preparation of amorphous Simeprevir sodium salt by spray- drying.
The spray-drying process is difficult to carry out on large scale and also is a time consuming process. Polymorphism is a property of some compounds. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties.
Polymorphs are different solids having the same molecular structure, yet having distinct physical properties when compared to other polymorphs of the same molecular structure. The discovery of new polymorphs and solvates of a pharmaceutical active compound provides an opportunity to improve the performance of a drug product in terms of its bioavailability or release profile in vivo, or it may have improved stability or advantageous handling properties. Polymorphism is an unpredictable property of any given compound. This subject has been reviewed in recent articles, including A. Goho, "Tricky Business," Science News, August 21, 2004. In general, one cannot predict whether there will be more than one form for a compound, how many forms will eventually be discovered, or how to prepare any previously unidentified form.
Hence there is a need to develop polymorphic forms of Simeprevir sodium and also an industrially feasible process for preparation of amorphous Simeprevir sodium salt. Description of drawing:
Figure 1 : illustrates X-ray powder diffraction pattern of substantially pure amorphous Simeprevir sodium designated as LI.
Figure 2: illustrates Differential Scanning Calorimetry (DSC) of LI.
Figure 3: illustrates X-ray powder diffraction pattern of substantially pure amorphous Simeprevir sodium designated as L2.
Figure 4: illustrates Differential Scanning Calorimetry (DSC) of L2. Summary of the invention:
In accordance with one embodiment, the present invention provides substantially pure amorphous forms of Simeprevir sodium designated as LI. In accordance with another embodiment, the present invention provides substantially pure amorphous forms of Simeprevir sodium designated as L2.
In accordance with another embodiment, the present invention provides the process for preparation of substantially pure amorphous forms of simeprevir sodium salt.
In accordance with another embodiment, the present invention provides for pharmaceutical compositions comprising said substantially amorphous forms of Simeprevir sodium. Detailed description:
The term "substantially pure amorphous" as used herein is intended to mean that amorphous Simeprevir sodium with certain degree of crystallinity. In one embodiment, the present invention provides Simeprevir sodium in a substantially pure amorphous form designated as LI, characterized by X-ray powder diffraction pattern as depicted in Fig. 1. The PXRD pattern of substantially pure amorphous Simeprevir sodium comprises of crystalline peaks at 8.05° ± 0. 2° 2Θ and 17.96° ± 0.2° 2Θ.
Further characterizing data for substantially pure amorphous Simeprevir sodium form LI according to the present invention as obtained by differential scanning calorimetry (DSC) is shown in FIG. 2.
In another embodiment, the present invention provides Simeprevir sodium salt in a substantially pure amorphous form designated as L2, characterized by X-ray powder diffraction pattern as depicted in Fig. 3. The PXRD pattern of substantially pure amorphous Simeprevir sodium comprises of crystalline peaks at 8.78° ± 0. 2° 2Θ, 11.36 ° ± 0.2° 2Θ and 29.69° ± 0.2° 2Θ.
Further characterizing data for substantially pure amorphous Simeprevir sodium form L2 according to the present invention as obtained by differential scanning calorimetry (DSC) is shown in FIG. 4.
In another embodiment the present invention provides process for preparing substantially pure amorphous Simeprevir sodium comprising:
(i) reacting Simeprevir free base with sodium ethyl hexanoate in an organic solvent;
(ii) adding anti-solvent to the mixture of step (i); and
(iii) isolating substantially pure amorphous Simeprevir sodium salt from reaction mixture thereof.
The organic solvent used in step (i) is selected from but not limited to methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, amyl alcohol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, dioxane and/or mixtures thereof. The reaction of step (i) is carried out at a temperature of 0°C to reflux temperature of the solvent.
The anti-solvent used in step (ii) is selected from but not limited to n-pentane, n-hexane, n- heptane, cyclohexane, toluene, xylene, and/or water and mixtures thereof.
The isolation of the substantially pure amorphous Simeprevir sodium salt is carried out by conventional techniques known in the prior art such as filtration, concentration, evaporation etc.; and drying the product include all techniques known to those skilled in the art, such as heating, applying vacuum, circulating air or gas, adding a desiccant, evaporation, or the like, or any combination thereof.
In another embodiment, the present invention provides a pharmaceutical composition comprising substantially pure amorphous form LI and form L2 of Simeprevir sodium with pharmaceutically acceptable excipients. Substantially pure amorphous form LI and form L2 of Simeprevir sodium can be formulated into various pharmaceutical compositions like powder, granules, capsules, tablets, pellets etc.
Pharmaceutically acceptable excipients may be utilized as required for conversion of the substantially amorphous form of Simeprevir sodium salt into the final pharmaceutical dosage forms and include, for example, any one or more of diluents, binders, stabilizers, lubricants, glidants, disintegrating agents, surfactants, and other additives that are commonly used in solid pharmaceutical dosage form preparations.
Examples:
The following examples describe the present invention in detail, but are not to be construed to be in any way limiting for the present invention.
Example 1:
Process for Preparation of substantially pure amorphous form LI of Simeprevir sodium To the slurry of Simeprevir freebase (0.5 g, 0.66 mmol) in Tetrahydrofuran (2.5 ml) was added a solution of sodium-2-ethyl hexanoate (0.166 g, 0.99 mmol) in Tetrahydrofuran (2.0 ml). Reaction mass was stirred for 45 mins followed by addition of n-Heptane (25 ml). Stirring was continued for additional 60 mins. The product was obtained by filtration and washing with n-Heptane (2.0 ml). The product was dried under vacuum to yield (0.38 g) Simeprevir Sodium.
Example 2:
To the slurry of Simeprevir (0.5 g, 0.66 mmol) in Acetone (5.0 ml), added a solution of sodium-2-ethyl hexanoate (0.166 g, 0.99 mmol) in Acetone (2.0 ml). Reaction mass was stirred for 20 mins followed by addition of n-Heptane (16 ml). Reaction mass was heated and stirred at 55°C for 60 mins. Reaction mass was then cooled to room temperature and stirred for 180 mins. The product is obtained by filtration and washing with n-Heptane (1.0 ml). The product was dried under vacuum to yield (0.32 g) Simeprevir Sodium.
Example 3:
Process for Preparation of substantially pure amorphous form L2 of Simeprevir sodium To the slurry of Simeprevir freebase (35 g, 0.0466 mmol) in Tetrahydrofuran (140ml) was added a solution of sodium-2-ethyl hexanoate (11.6 g, 0.0699 mmol) in Tetrahydrofuran (105 ml). Reaction mass was stirred for 45 mins followed by addition of n-Heptane (1750 ml). Stirring was continued for additional 60 mins. The product was obtained by filtration and washing with n-Heptane (175 ml). The product was dried under vacuum to yield (35.8 g) Simeprevir Sodium.

Claims

1. Substantially pure amorphous Simeprevir sodium salt designated as LI.
2. The substantially pure amorphous Simeprevir sodium salt LI according to the claim 1 is characterized by X-Ray diffraction pattern comprising crystalline peaks at 8.05° ± 0. 2°
2Θ and 17.96° ± 0.2° 2Θ.
3. The substantially pure amorphous Simeprevir sodium salt LI of claim 1, characterized as having X-ray powder diffraction pattern substantially the same as that shown in FIG. 1.
4. The substantially pure amorphous Simeprevir sodium salt according to claim 1 having Differential Scanning Calorimetry (DSC) curve as shown in Fig 2.
5. Substantially pure amorphous Simeprevir sodium salt designated as L2.
6. Substantially pure amorphous Simeprevir sodium salt L2 according to claim 5 is characterized by X-Ray diffraction pattern comprising crystalline peaks at 8.78° ± 0. 2° 2Θ, 11.360 ± 0.2° 2Θ and 29.69° ± 0.2° 2Θ.
7. The substantially pure amorphous Simeprevir sodium salt L2 of claim 5, characterized as having X-ray powder diffraction pattern substantially the same as that shown in FIG. 3.
8. Substantially pure amorphous Simeprevir sodium salt according to claim 5 having Differential Scanning Calorimetry (DSC) curve as shown in Fig 4.
9. A process for the preparation of substantially pure amorphous Simeprevir sodium salt LI and L2 comprising:
(i) reacting Simeprevir free base with sodium ethyl hexanoate in an organic solvent;
(ii) adding anti-solvent to the mixture of step (i); and
(iii) isolating amorphous Simeprevir sodium salt from reaction mass thereof.
10. The improved process according to claim 9, wherein the organic solvent used in step (i) is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, amyl alcohol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, dioxane and/or mixtures thereof.
11. The improved process according to claim 9, wherein the anti-solvent used in step (ii) is selected from n-pentane, n-hexane, n- heptane, cyclohexane, toluene, xylene, and/or water and mixtures thereof.
12. A pharmaceutical composition comprising substantially pure amorphous form LI or form L2 of Simeprevir sodium and a pharmaceutically acceptable carrier, excipients or diluent.
13. The pharmaceutical composition of claim 12 wherein said pharmaceutical composition is suitable for oral administration to patient.
PCT/IB2016/054446 2015-07-27 2016-07-26 Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof WO2017017604A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2849MU2015 2015-07-27
IN2849/MUM/2015 2015-07-27

Publications (2)

Publication Number Publication Date
WO2017017604A1 true WO2017017604A1 (en) 2017-02-02
WO2017017604A9 WO2017017604A9 (en) 2017-04-06

Family

ID=56684131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/054446 WO2017017604A1 (en) 2015-07-27 2016-07-26 Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2017017604A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306634A1 (en) 2009-02-27 2011-12-15 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Amorphous Salt of a Macrocyclic Inhibitor of HCV
WO2016054240A1 (en) * 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306634A1 (en) 2009-02-27 2011-12-15 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Amorphous Salt of a Macrocyclic Inhibitor of HCV
WO2016054240A1 (en) * 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. GOHO: "Tricky Business", SCIENCE NEWS, 21 August 2004 (2004-08-21)

Also Published As

Publication number Publication date
WO2017017604A9 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
JP7123429B2 (en) Bicyclic fused ring system nucleocapsid inhibitors and their use as drugs to treat hepatitis B
WO2011095059A1 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
TW200418806A (en) HDAC inhibitor
EP4092037A1 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
CN1950376A (en) Curcumol derivatives, compositions comprising the same and use in manufacture of medicament
WO2010139979A2 (en) Processes for preparing crystalline forms
WO2016038542A2 (en) Polymorphic forms of sofosbuvir
CN108250121A (en) Sulfonamide-arylamides and its medicinal usage for treating hepatitis B
CN106883279A (en) A kind of prodrug, its preparation method, medical composition and its use
CN101775003B (en) Benzothiophene derivative, preparation method and application thereof
CN105732468A (en) N'-(2-(1H-indole-3-yl)acetyl)arylhydrazide compound and preparation method and application thereof
CN111655691B (en) Liver delivery entecavir prodrug nucleoside cyclic phosphate ester compound and application thereof
US11466031B2 (en) Polymorphic forms of bictegravir and its sodium salt
CN108129366B (en) Antiviral compounds, methods of preparation and uses thereof
WO2017017604A1 (en) Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof
CN113614088A (en) Solid forms of HBV core protein allosteric modifier compounds
CN112204035A (en) Substituted 3,4,12,12 a-tetrahydro-1 n1- [1,4] oxazino [3,4-c ] pyrido [2,1-f ] [1,2,4] triazine-6, 8-diones, pharmaceutical compositions, methods of production and uses thereof
WO2020151296A1 (en) Dinucleotide precursor for drug and preparation method therefor
US11008361B2 (en) Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof
WO2018184392A1 (en) Indoleamine 2,3-dioxygenase inhibitor containing hydrazino group
WO2024146631A1 (en) Preparation method for parp7 inhibitor
US20200247787A1 (en) Troxacitabine synthesis and crystal form thereof
CN109810063A (en) A kind of novel resisiting influenza virus " twin medicine ", preparation method and the usage
WO2015109925A1 (en) Crystalline form of hepatitis c drug and preparation method, pharmaceutical composition and use thereof
WO2015180253A1 (en) Crystalline form of anti-hepatitis c virus drug, preparation method therefor, and pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16751012

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16751012

Country of ref document: EP

Kind code of ref document: A1